Small molecule · developed by PFIZER
PF-08032562 is a drug studied in advanced and metastatic breast cancer, including HR-positive/HER2-negative and triple negative breast cancer, and in metastatic colorectal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
Advanced Breast CancerColorectal CancerMetastatic Breast Cancer (HR+/ HER2-)Metastatic Colorectal AdenocarcinomaTriple Negative Breast Cancer
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →